An Open Label, Dose Escalation Safety and Tolerability Trial of the Combination of s.c. Recombinant Human IL-21 (rIL-21) and Sunitinib (Phase 1) Followed by an Open Label Stratified Randomized 2-arm Trial of rIL-21 Plus Sunitinib Versus Sunitinib Alone (Phase 2a) in Subjects With Stage IV Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Denenicokin (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 01 Nov 2012 Planned number of patients changed from 9 to 135.
- 29 Aug 2012 New source identified and integrated (DRKS00004053: German Clinical Trials Register).
- 19 Jan 2009 Planned number of patients changed from 18 to 9, as reported by ClinicalTrials.gov.